



Role of Glycomics in Diagnosis and Prognosis of Cancers

Guest Editor:

Dr. Tijl Vermassen

1. Department Medical Oncology,
University Hospital Ghent, 9000
Ghent, Belgium

2. Department Basic and Applied
Medicine, Ghent University, 9000
Ghent, Belgium

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

A multitude of -omic fields are being studied for their involvement in cancer. For a long time, glycoproteins have been of great interest in biomarker research as many changes in protein chemistry can be associated with actual changes in protein glycosylation.

This variation seen in the glycome is the result of genetic and environmental factors, which also play a major role in the onset of many disease. Therefore, variations in glycosylation patterns have been linked to a multitude of pathological conditions, providing precious insight into the cellular functions underlying these pathological conditions.

In this Special Issue, we aim to cover the most recent advances regarding glycomic research in cancer. The main focus will be on, but not limited to, the pathophysiological role of the glycome in cancer development and progression, use of glycans for disease diagnosis, risk stratification and prognosis through glycan variation, as well as innovative tools and methodological approaches to assess glycan-related biomarkers.

In this Special Issue, we welcome any kind of papers on the aforementioned subject.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)